Telehealth usage low due to reimbursement, training, licensing

Fifteen percent of primary care respondents to a survey on telehealth said they use telehealth in their practices.

The American Academy of Family Physicians, the Robert Graham Center and Anthem conducted the survey in January.

Telehealth users are more likely rural, younger, in practice for fewer than 10 years and were more likely to employ an EMR than non-users. Users are likely to provide a broad scope of services, like emergency or procedural care but the most common telehealth method cited was real-time video consultations.

Frequent purposes included: diagnosis, treatment, chronic disease management, obtaining a second opinion and providing follow-up care. 

The most common barriers to telehealth usage cited by respondents include the following:

  • Concerns about proper reimbursement;
  • Lack of training for both physicians and staff;
  • Issues with technological platforms; and
  • Licensing and credentialing.

Both users and non-users believe that telehealth has the potential to improve access to care, improve continuity and decrease travel time for patients. Respondents agreed that in-person care was best, but also recognized that services via telehealth is a good way to improve access to care for their patients. 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.